Michael F. Bigham
Chief Executive Officer and Chairman of the Board
Michael F. Bigham was appointed Chief Executive Officer and Chairman of our Board of Directors in October 2014. Mr. Bigham has more than 25 years of senior leadership experience in the biopharmaceutical industry. From January 2003 to November 2015, he was a general partner at Abingworth LLP, a leading international investment group dedicated to life sciences and healthcare. In November 2015, Mr. Bigham became part time Executive Partner at the firm. He currently serves as a member of the board of directors of Adamas Pharmaceuticals and InMediata. He has held several directorships, including at Avila Therapeutics (where he was also the founding Chairman and CEO), Magellan Biosciences, Portola Pharmaceuticals, Supernus Pharmaceuticals, Avedro and Valeritas. Mr. Bigham was formerly Vice Chairman of Corixa Corporation, a publicly traded biotechnology company, and was President and Chief Executive of Coulter Pharmaceuticals, a publicly-traded oncology company, until it merged into Corixa. Previously, he was an early employee at Gilead Sciences where he served in various capacities, including Executive Vice President of Operations and Chief Financial Officer. Before joining Gilead Sciences, Mr. Bigham was a Partner at Hambrecht & Quist where he became Co-Head of Healthcare Investment Banking. Mr. Bigham received his B.S. from the University of Virginia and qualified as a C.P.A. before completing his M.B.A. at Stanford University.
Evan Loh, M.D.
President, Chief Operating Officer and Chief Medical Officer
Evan Loh, M.D. has served as Chief Operating Officer since January 2017 and as President and Chief Medical Officer and a member of the Board of Directors since July 2014. Prior to the merger with Transcept Pharmaceuticals, Dr. Loh was appointed President in June 2014 and served as Chief Medical Officer and Chairman of the Board of Directors from June 2012 to June 2014. Previously, Dr. Loh served as Senior Vice President, Development and Strategic Operations, Worldwide Research and Development, at Pfizer. While at Pfizer, Dr. Loh’s responsibilities included scientific, operational, and strategic drug development oversight for all pre-proof of concept development phase programs and leading portfolio prioritization. Dr. Loh joined Pfizer from Wyeth Pharmaceuticals, where he was Vice President, Multiple Therapeutic Areas where he was responsible for global development strategy and clinical operational deliverables. At Wyeth, he led the successful global registration programs for Torisel and Tygacil. He currently serves as Vice Chair of the Antimicrobials Working Group, an industry leading organization of biotech companies focused on antimicrobial development. Dr. Loh served as a director on the Board of Nivalis (Nasdaq: NVLS) from 2012 until the completion of its sale to Alpine Immunotherapeutics (Nasdaq: ALPN) in 2017. Dr. Loh served as a faculty member at both Harvard Medical School and the University of Pennsylvania School of Medicine. Dr. Loh received his A.B. from Harvard College and his M.D. from Harvard Medical School. He completed his Internal Medicine and Cardiovascular fellowship training at Brigham and Women’s Hospital.
Douglas W. Pagán
Chief Financial Officer
Douglas W. Pagán joined Pino in December 2014 as Chief Financial Officer. He most recently served as Vice President, Finance at Acceleron Pharma Inc., which he joined in 2008. There, he was instrumental in the company's successful IPO as well as multiple rounds of private and public equity and debt financings. Prior to working at Acceleron, Mr. Pagán served in strategic and financial management roles at Biogen Idec and Bristol-Myers Squibb. Previously, Mr. Pagán worked in healthcare investment banking at J.P. Morgan, as well as pharmaceutical operational roles at Johnson and Johnson. Mr. Pagán received his BSE in Chemical Engineering from Princeton University and his MBA from Columbia Business School.
Chief Commercial Officer
Adam Woodrow joined Pino in October 2014 to lead the commercialization of Pino’s product portfolio. Adam previously worked for Pfizer for five years in various strategic and operational commercial roles. While at Pfizer, Adam led the commercial development group in Pfizer's Specialty Care Business Unit, launching Xeljanz® for Rheumatoid Arthritis and Vyndaqel® for the treatment of Transthyretin Familial Amyloid Polyneuropathy (TTR-FAP). In addition, Adam led the global strategic marketing teams for a variety of products in fields ranging from rare disease to acute hospital based infections; major products included Enbrel®, Zyvox®, ReFacto® and Benefix®. Adam joined Pfizer from Wyeth Pharmaceuticals, where he was Vice President and Global Business Manager for Enbrel leading all commercial aspects of Wyeth's inflammation portfolio, co-promotion, licensing, and product development. In his 10 years at Wyeth, Adam held senior marketing and sales positions in the US and in his native UK. He was responsible for the successful launches of medicines in the fields of anti-infectives (Tygacil®), hemophilia (ReFacto), primary immune deficiency and women's health. Before joining Wyeth, Adam held sales and marketing positions with Bayer Pharmaceuticals. During his career in the pharmaceutical industry, Adam has worked with several non-profit societies and organizations. Adam has a Bachelor of Science degree in Industrial Chemistry from the University of Wales College of Cardiff.
General Counsel and Corporate Secretary
William Haskel joined Pino in June 2015 as Senior Vice President, General Counsel and Corporate Secretary. From 2011 until March 2015, Bill served as the Senior Vice President, General Counsel, Chief Compliance Officer and Corporate Secretary at Cambrex Corporation, where he reported to the CEO, and was a member of core management committees. Bill provided counsel to the Board of Directors, CEO, and senior management, and was responsible for the global law function as well as overseeing Global Regulatory and Quality Affairs, and Environment, Health and Safety and was a principal adviser for Board and Governance, M&A, Securities and Corporate matters. Previously, Bill enjoyed an 18 year career of progressive responsibilities at Wyeth, which was acquired by Pfizer in 2009 in a transaction valued at $68 billion. Bill served as Vice President and Associate General Counsel-Corporate where he was a key advisor to executive management and managed a group of 33 employees/19 lawyers across corporate and pharmaceutical division headquarters, and led legal teams on a series of complex multi-billion dollar global transactions that drove the Company's transition from a diversified holding company to a focused health care company. Bill also served as Vice President, Global Administration where he led a newly formed global department charged with designing and executing global strategies to capture cost savings and business efficiencies in light of the new health care environment. During this time, Bill also served as Advisor for the Pfizer Transaction and was a leader of the successful integration of Wyeth into Pfizer. Earlier at Wyeth, Bill was selected to be the Assistant Vice President, Planning; Assistant to the Chairman, President and CEO; and Secretary of Wyeth Management Committee. Earlier in his career, Bill was a corporate associate at the law firms Hale & Dorr (now WilmerHale) in Boston, and Olwine, Connelly, Chase, O'Donnell & Weyher in New York City. He received his J.D. from George Washington University Law School; his B.A. from Franklin and Marshall College; and has Bar Admissions in New York State; Commonwealth of Massachusetts; New Jersey (Limited In-House License), and the United States District Court (District of Massachusetts).